UPCC 47423:A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

TrAVeRse is a multicenter, open-label, randomized, Phase II study of AVR in treatment naive MCL participants. The primary objective is to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at end of AVR induction will be randomized to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib. We would like to rely on WCG as the IRB of record.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All